ATRC

NEUTRALEarnings

AtriCure, Inc.

2026-10-26

Price

$61.08

+3.58%

This is the 2026-10-26 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score5.5Watchlist

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

ATRC's sustained breakout is fundamentally driven by clinical momentum from its BoxX-NoAF trial and favorable STS quality metrics, which have sparked a recent wave of analyst upgrades. By shrugging off valuation concerns and insider selling to hold at its 52-week high, the stock is exhibiting High-Conviction Price Discovery and Institutional Absorption. Within a CAUTION macro regime where high-beta and momentum names are catching aggressive bids, ATRC's PERFECT_STACK and QUIET_ACCUMULATION signals confirm steady institutional backing ahead of its November earnings.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONINSIDE OUT

Key Takeaways

Technicals align with fundamental catalysts, with ATRC consolidating at 52-week highs following recent analyst price target hikes, including Citizens JMP to $68.
Elevated valuation metrics and ongoing 10b5-1 insider sales by the CTO pose headline risks that could cap upside if forward guidance disappoints.
Watch the $52.84 support level to defend the structural uptrend, with the Q3 earnings print acting as the primary near-term catalyst.

← Back to 2026-10-26 View Full ATRC History →Yahoo Finance &nearr;